Exploring the complexities of drug formulation selection, storage, and shelf-life for exploration spaceflight

被引:1
作者
Daniels, Vernie R. [1 ,3 ]
Williams, Edward S. [2 ]
机构
[1] KBR, Houston, TX 77058 USA
[2] NASA, Johnson Space Ctr, Houston, TX 77058 USA
[3] NASA Johnson Space Ctr, Biomed Res & Environm Sci Div, KBR, Human Hlth & Performance Contract, Houston, TX 77058 USA
关键词
drug degradation risk assessment; drug repurposing; drug storage and packaging; innovative drug delivery systems; spaceflight drug formulary optimization; spaceflight pharmaceutical stability; STABILITY; FOOD; SPECTROSCOPY; FILMS; PHARMACEUTICALS; PHOTOSTABILITY; CELLULOSE; QUALITY; RESINS; RISK;
D O I
10.1111/bcp.15957
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Medications have been a part of space travel dating back to the Apollo missions. Currently, medical kits aboard the International Space Station (ISS) contain medications and supplies to treat a variety of possible medical events. As we prepare for more distant exploration missions to Mars and beyond, risk management planning for astronaut healthcare should include the assembly of a medication formulary that is comprehensive enough to prevent or treat anticipated medical events, remains safe and chemically stable, and retains sufficient potency to last for the duration of the mission. Emerging innovation and technologies in pharmaceutical development, delivery, quality maintenance, and validation offer promise for addressing these challenges. The present editorial will summarize the current state of knowledge regarding innovative formulary optimization strategies, pharmaceutical stability assessment techniques, and storage and packaging solutions that could enhance drug safety and efficacy for future exploration spaceflight missions.
引用
收藏
页数:10
相关论文
共 114 条
  • [1] Nano-silymarin provides protection against γ-radiation-induced oxidative stress in cultured human embryonic kidney cells
    Adhikari, Manish
    Arora, Rajesh
    [J]. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2015, 792 : 1 - 11
  • [2] Point-of-care production of therapeutic proteins of good-manufacturing-practice quality
    Adiga, Rajani
    Al-adhami, Mustafa
    Andar, Abhay
    Borhani, Shayan
    Brown, Sheniqua
    Burgenson, David
    Cooper, Merideth A.
    Deldari, Sevda
    Frey, Douglas D.
    Ge, Xudong
    Guo, Hui
    Gurramkonda, Chandrasekhar
    Jensen, Penny
    Kostov, Yordan
    LaCourse, William
    Liu, Yang
    Moreira, Antonio
    Mupparapu, KarunaSri
    Penalber-Johnstone, Chariz
    Pilli, Manohar
    Punshon-Smith, Benjamin
    Rao, Aniruddha
    Rao, Govind
    Rauniyar, Priyanka
    Snovida, Sergei
    Taurani, Kanika
    Tilahun, Dagmawi
    Tolosa, Leah
    Tolosa, Michael
    Tran, Kevin
    Vattem, Krishna
    Veeraraghavan, Sudha
    Wagner, Brandon
    Wilhide, Joshua
    Wood, David W.
    Zuber, Adil
    [J]. NATURE BIOMEDICAL ENGINEERING, 2018, 2 (09): : 675 - 686
  • [3] Improved properties of keratin-based bioplastic film blended with microcrystalline cellulose: A comparative analysis
    Alashwal, Basma Y.
    Bala, Mohamed Saad
    Gupta, Arun
    Sharma, Swati
    Mishra, Puranjan
    [J]. JOURNAL OF KING SAUD UNIVERSITY SCIENCE, 2020, 32 (01) : 853 - 857
  • [4] American Association for the Advancement of Science (AAAS), 2022, Reports and Proceedings, CS
  • [5] [Anonymous], 2003, International conference on harmonization of technical requirements for registration of Pharmaceuticals for Human use (ICH) Q1A (R2), Stability testing of new pharmaceutical products
  • [6] [Anonymous], 2009, Pharmaceutical Development Q8(R2)
  • [7] Antonsen E., 2016, Conceptual Drivers for an Exploration Medical System
  • [8] Antonsen E., 2020, Human system risk management plan
  • [9] Antonsen EL., 2019, J Health L POL'y, P1
  • [10] Estimating medical risk in human spaceflight
    Antonsen, Erik L.
    Myers, Jerry G.
    Boley, Lynn
    Arellano, John
    Kerstman, Eric
    Kadwa, Binaifer
    Buckland, Daniel M.
    Van Baalen, Mary
    [J]. NPJ MICROGRAVITY, 2022, 8 (01)